OB-756 is under clinical development by Hangzhou East China Pharmaceutical Group and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OB-756’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OB-756 is under development for the treatment of rheumatoid arthritis, primary myelofibrosis, post-essential thrombocythemia myelofibrosis (Post-ET MF) and post-polycythemia vera myelofibrosis (PPV-MF). The drug candidate is administered by the oral route. The drug candidate is an OB-756 film. The drug candidate acts by targeting Janus kinase 1 (JAK-1) and Janus kinase 2 (JAK-2).
For a complete picture of OB-756’s drug-specific PTSR and LoA scores, buy the report here.